Didanosine

CD4 molecule ; Homo sapiens







56 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 27088320 Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. 2016 Jul 17 1
2 21087377 Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. 2011 Feb 1
3 19207595 Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. 2009 Mar 3
4 19432547 Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. 2009 Jun 1 1
5 19737231 Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. 2009 Oct 1
6 18546542 Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. 2008 May 2
7 17341536 CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction. 2007 Mar 6
8 17434879 CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. 2007 Jun 1
9 18025882 Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. 2007 Nov 30 1
10 16531427 Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. 2006 May 2
11 16717052 Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. 2006 Jul 1
12 16956530 [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression]. 2006 Aug-Sep 7
13 15802975 Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. 2005 Mar 24 1
14 15865227 Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. 2005 1
15 15958845 Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. 2005 Jul 1 4
16 16107993 Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. 2005 Sep 15 1
17 16312178 Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. 2005 1
18 15090798 Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. 2004 Feb 20 3
19 15259896 Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. 2004 Jun 1
20 15622326 CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. 2004 Dec 3 1
21 12803944 Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. 2003 May 1
22 11865396 T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy. 2002 Feb 15 1
23 12215207 L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. 2002 Jun 1
24 10671348 Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. 2000 Feb 1
25 11101059 Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. 2000 Nov 10 1
26 9928724 A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. 1999 Jan 1 1
27 10395849 The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. 1999 Aug 1
28 10428106 Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. 1999 Aug 1 1
29 10534145 Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. 1999 Sep 1 1
30 10651392 Didanosine: an updated review of its use in HIV infection. 1999 Dec 2
31 16021874 Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. 1999 1
32 10503166 A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. 1998 2
33 11322267 Zidovudine plus didanosine in primary HIV-1 infection. 1997 Jan 1
34 11327443 Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. 1997 Dec 1
35 8556398 Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. 1996 Feb 1 2
36 8603961 Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial. 1996 Apr 1
37 8605592 Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV. 1996 Apr 15 2
38 8673528 Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. 1996 Jul 1
39 8898668 A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. 1996 Nov 1 2
40 8997487 Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. 1996 Dec 1
41 11322250 Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients. 1996 Aug 2
42 7677296 Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. 1995 Oct 15 4
43 7718186 Response of HIV RNA to didanosine as a predictive marker of survival. 1995 Feb 1
44 7751692 Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection. 1995 May 1
45 8595509 Studies of zidovudine in combination with didanosine and zalcitabine. 1995 2
46 8721897 A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3. 1995 4
47 7840911 HIV therapy advances. Pediatric antiretroviral choices. 1994 Sep 2
48 7888537 Rates and risk factors for adverse events associated with didanosine in the expanded access program. 1994 Dec 1
49 7905722 Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. 1994 Mar 1 1
50 8093845 Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. 1993 Feb 1